Results 81 to 90 of about 55,581 (203)

Reduced‐Dose Bendamustine as a First‐Line Treatment of Follicular Lymphoma Is Associated With Poorer Prognosis

Cancer Medicine, Volume 15, Issue 3, March 2026.
ABSTRACT The dose of bendamustine used to treat previously untreated follicular lymphoma (FL) is sometimes reduced based on various clinical considerations, but the impact of such dose reductions on outcomes is unclear. We retrospectively analyzed 92 untreated FL patients treated with bendamustine at seven institutions in Japan.
Keisuke Tanaka, Atsushi Takahata, Yuma Noguchi, Keigo Okada, Tatsuya Saito, Junichi Mukae, Yuki Osada, Ken Suzuki, Daisuke Mizuchi, Koh Yamamoto, Takashi Kumagai, Gaku Oshikawa, Takehiko Mori, Shigeo Toyota, Masahide Yamamoto   +14 more
wiley   +1 more source

Expression of sIL-2R before and after chemotherapy in patients with breast cancer

Chinese Journal of Cancer Research, 2008
To investigate the difference of peripheral blood sIL-2R before and after chemotherapy in breast cancer patients, and evaluate the clinical value of the sIL-2R in breast cancer’s diagnosis and therapy. The peripheral blood sIL-2R levels of the breast cancer patients with or without chemotherapy were detected by ELISA.
Yuan-ming Fan, Zhi-jun Sun
openaire   +1 more source

Positive correlation between number of CD68-positive macrophages and sIL-2R levels.

, 2013
We counted the number of CD68- or CD163-positive macrophages in DLBCL, FL and RLH. Representative images of CD68-positive or CD163-positive macrophages in DLBCL and FL are shown (A–D).
Yoshito Sadahira (483945), Akira Sakai (198243), Hideki Asaoku (483946), Noriaki Yoshida (483937), Masao Seto (73894), Keichiro Mihara (103116), Yuta Katayama (135414), Takashi Nishisaka (483943), Akiro Kimura (483948), Megumu Fujiwara (483942), Naomi Sasaki (483944), Yoshiaki Kuroda (483939), Miyo Oda (483938), Taro Masunari (483941), Yoshiko Okikawa (483940), Koji Arihiro (56456), Hirotaka Matsui (483947)   +16 more
core   +1 more source

Thyroid stimulating immunoglobulin concentration is associated with disease activity and predicts response to treatment with intravenous methylprednisolone in patients with Graves’ orbitopathy

Frontiers in Endocrinology
BackgroundThyroid stimulating immunoglobulins (TSI) play a central role in the pathogenesis of Graves’ orbitopathy (GO), while soluble interleukin-2 receptor (sIL-2R) is a marker for T-cell activity.
Gijsbert J. Hötte, P. Martijn Kolijn, Maaike de Bie, Maaike de Bie, Ronald O. B. de Keizer, Marco Medici, Kim van der Weerd, P. Martin van Hagen, P. Martin van Hagen, Dion Paridaens, Dion Paridaens, Willem A. Dik   +11 more
doaj   +1 more source

Soluble Interleukin-2 Receptors in Patients with Advanced Colorectal Carcinoma

The International Journal of Biological Markers, 1996
The levels of soluble interleukin-2 receptors (sIL-2R) were measured in the serum of 52 patients with advanced colorectal carcinoma and compared to CEA and CA 19-9 levels. Twenty-five normal, age and sex-matched individuals served as controls.
N. Pavlidis, C. Nicolaides, E. Bairaktari, J. Kalef-Ezra, A. Athanassiadis, C. Seferiadis, G. Fountzilas   +6 more
doaj   +1 more source

Elevated Plasma Levels of sIL-2R in Complex Regional Pain Syndrome: A Pathogenic Role for T-Lymphocytes? [PDF]

, 2020
The immune system has long been thought to be involved in the pathophysiology of complex regional pain syndrome (CRPS). However, not much is known about the role of the immune system and specifically T-cells in the onset and maintenance of this disease ...
Dirk L Stronks, Willem A Dik, Krishna D Bharwani, Maaike Dirckx, Frank J P M Huygen, Marco W J Schreurs   +5 more
core  

Diagnostic value of soluble Interleukin-2 receptor in patients suffering neurosarcoidosis: A systematic review

Journal of Central Nervous System Disease
Background Neurosarcoidosis is an inflammatory granulomatous disease. Up to 25% of occult sarcoidosis affecting the nervous system are only detected by autopsy. In addition, in recent years the suspicion arose that the soluble Interleukin-2 Receptor (sIL-
Aditya Chanpura, Rajesh K. Gupta, Shitiz K. Sriwastava, Jan Rahmig   +3 more
doaj   +1 more source

Serum level of soluble interleukin‐2 receptor is positively correlated with metabolic tumor volume on 18F‐FDG PET/CT in newly diagnosed patients with diffuse large B‐cell lymphoma

Cancer Medicine, 2019
Diffuse large B‐cell lymphoma (DLBCL) is the most frequent subtype of non‐Hodgkin lymphoma. High total metabolic tumor volume (TMTV) calculated using 18F‐FDG PET/CT images at diagnosis predicts poor prognosis of patients with DLBCL.
Hajime Senjo, Minoru Kanaya, Koh Izumiyama, Koichiro Minauchi, Kenji Hirata, Akio Mori, Makoto Saito, Masanori Tanaka, Hiroaki Iijima, Eriko Tsukamoto, Kazuo Itoh, Shuichi Ota, Masanobu Morioka, Daigo Hashimoto, Takanori Teshima, North Japan Hematology Study Group (NJHSG)   +15 more
doaj   +1 more source

Chronic Effects of Subcutaneous Interleukin-2 Therapy on Soluble Interleukin-2 Receptors in Advanced Small Cell Lung Cancer

The International Journal of Biological Markers, 1993
The increase in IL-2 receptor serum levels is one of the most typical changes in immune parameters during IL-2 cancer immunotherapy. To better define the effects of prolonged IL-2 injection on SIL-2R levels, we evaluated 7 advanced small cell lung cancer
S. Viviani, P.M. Salvini, P. Bidoli, E. Camerini, S. Spinazzé, F. Arienti, L. Rivoltini, V. Motta   +7 more
doaj   +1 more source

YKL-40, Soluble IL-2 Receptor, Angiotensin Converting Enzyme and C-Reactive Protein: Comparison of Markers of Sarcoidosis Activity

Biomolecules, 2018
The aims of this study were to describe the clinical, radiological and immunological features of a population of sarcoidosis patients and to analyse chitinase-3-like protein 1 (YKL-40), soluble interleukin-2 receptor (sIL-2R), neopterin concentrations ...
Pelin Uysal, Sinem Durmus, Volkan Sozer, Remise Gelisgen, Ekrem Cengiz Seyhan, Fusun Erdenen, Gonul Simsek, Hafize Uzun   +7 more
doaj   +1 more source